1,4 piperizino inhibitors of non-enzymatic cross-linking of prot

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

544402, C07D24104, A61K 31495

Patent

active

053568958

ABSTRACT:
The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises; an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. the method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

REFERENCES:
patent: 4665192 (1987-05-01), Cerami
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4908446 (1990-03-01), Ulrich et al.
patent: 5140048 (1992-08-01), Ulrich et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

1,4 piperizino inhibitors of non-enzymatic cross-linking of prot does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1,4 piperizino inhibitors of non-enzymatic cross-linking of prot, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4 piperizino inhibitors of non-enzymatic cross-linking of prot will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2372601

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.